Association Between Diabetes Medications and the Risk of Parkinsons Disease: A Systematic Review and Meta-Analysis
| Autor: | Xia Zhang, Min Wang, Zeqing Bao, Li Yan, Xiaocui Qin, Qili Liu, Pinyu Li |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
glucagon-like peptide-1 agonists
0301 basic medicine medicine.medical_specialty Parkinson's disease medicine.drug_class Disease 03 medical and health sciences 0302 clinical medicine Diabetes mellitus Internal medicine medicine glitazones sulfonylureas In patient RC346-429 business.industry Glucagon-like Peptide-1 Agonists medicine.disease Sulfonylurea Metformin 030104 developmental biology Neurology Meta-analysis Neurology. Diseases of the nervous system Systematic Review Neurology (clinical) metformin dipeptidyl peptidase-4 inhibitors business 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | Frontiers in Neurology Frontiers in Neurology, Vol 12 (2021) |
| ISSN: | 1664-2295 |
| DOI: | 10.3389/fneur.2021.678649 |
| Popis: | Background: Diabetes mellitus (DM) increases the risk of Parkinson's disease (PD). However, whether DM medications play a part on that increased PD risk is unclear. We designed this meta-analysis to assess the influence of different oral DM medications on the PD risk in patients with DM.Methods: We searched PubMed, Embase, and CENTRAL databases for relevant studies up until January 2021. We pooled adjusted outcomes to assess the PD risk in patients using different DM medications including sulfonylurea, metformin, glitazones (GTZ), dipeptidyl peptidase-4 inhibitors (DPP4i), and glucagon-like peptide-1 agonists (GLP1a).Results: We included 10 studies in our analysis. Our results indicate a lack of significant association between the PD risk and the use of sulfonylureas (three studies; HR, 1.26; 95% CI, 0.95 to 1.66; I2, 70%; p = 0.11), DPP4i (three studies; HR, 0.69; 95% CI, 0.35 to 1.38; I2, 88%; p = 0.30), metformin (five studies; HR, 1.23; 95% CI, 0.98 to 1.78; I2, 84%; p = 0.13), and GTZ (six studies; HR, 0.88; 95% CI, 0.66 to 1.16; I2, 92%; p = 0.35). After exclusion of a single study in the GTZ analysis, our results indicate a significantly reduced PD risk with GTZ use (HR, 0.78; 95% CI, 0.65 to 0.93; I2, 59%; p = 0.06). Similarly, after the exclusion of a single study, our results indicate a significantly increased PD risk with the use of metformin (HR, 1.50; 95% CI, 1.11 to 2.02; I2, 80%; p = 0.008). We also found a significantly reduced PD risk with the use of GLP1a (two studies; HR, 0.41; 95% CI, 0.19 to 0.87; I2, 0%; p = 0.02).Conclusion: The role of different DM medications on the PD risk remains unclear, and the quality of studies is low. While our analysis suggests a lack of association between the use of metformin, GTZ, DPP4i, and sulfonylureas and the PD risk, metformin (to a higher degree) and GTZ may still increase the risk. Limited data suggest a protective effect of GLP1a on the PD risk. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|